← All trials
NCT05169944
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 22, 2022
- Primary completion
- Feb 28, 2025
- Completion date
- Feb 28, 2025
- First posted
- Dec 27, 2021
- Last posted
- Oct 28, 2022
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- Gilead SciencesCollaborator
- Harvard UniversityStudy chair
- University of California, San FranciscoOverall official - principal investigator
- University of California, San FranciscoReponsible party - principal investigator
- University of UtahStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.